Current and Resolved Drug Shortages and Discontinuations Reported to FDA
Report a Drug Shortage |
Contact Us |
FAQ |
Background Info |
Get Email Alerts |
Download Current Drug Shortages
Start Over | Back to Search Results
Amoxicillin Oral Powder for Suspension
Status: Currently in Shortage
»Date first posted:
10/28/2022
»Therapeutic Categories: Anti-Infective; Pediatric
Aurobindo, USA (Reverified 01/11/2023)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| 125 mg/5mL (NDCs 65862-706-01, 65862-706-55, and 65862-706-80) | On allocation. | Demand increase for drug | |
| 200 mg/5mL (NDCs 65862-070-01, 65862-070-50, and 65862-070-75) | On allocation. | Demand increase for drug | |
| 250 mg/5mL (NDCs 65862-707-01, 65862-707-55, and 65862-707-80) | On allocation. | Demand increase for drug | |
| 400 mg/5mL (NDCs 65862-071-01, 65862-071-50, and 65862-071-75) | On allocation. | Demand increase for drug |
Hikma Pharmaceuticals (Reverified 05/31/2023)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| 125 mg/5mL (NDCs 0143-9888-01, 0143-9888-15, and 0143-9888-80) | Available for current customers. | Demand increase for drug | |
| 200 mg/5mL (NDCs 0143-9886-01, 0143-9886-50, and 0143-9886-75) | Available for current customers. | Demand increase for drug | |
| 250 mg/5mL (NDCs 0143-9889-01, 0143-9889-15, and 0143-9889-80) | Available for current customers. | Demand increase for drug | |
| 400 mg/5mL (NDCs 0143-9887-01, 0143-9887-50, and 0143-9887-75) | Available for current customers. | Demand increase for drug |
Sandoz (Reverified 05/26/2023)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| 125mg/5mL 100 mL (NDC 0781-60-3946) | Limited Availability | Other | |
| 125mg/5mL 150 mL (NDC 0781-60-3955) | Limited Availability | Other | |
| 250 mg/5 mL 80 mL (NDC 0781-60-3958) | Limited Availability | Other | |
| 200 mg/5 mL 100 mL (NDC 0781-61-5646) | Limited Availability | Other | |
| 200 mg/5 mL 50 mL (NDC 0781-61-5652) | Limited Availability | Other | |
| 200 mg/5 mL 75 mL (NDC 0781-61-5657) | Limited Availability | Other | |
| 400 mg/5 mL 100 mL (NDC 0781-61-5746) | Limited Availability | Other | |
| 400 mg/5 mL 50 mL (NDC 0781-61-5752) | Limited Availability | Other | |
| 400 mg/5 mL 75 mL (NDC 0781-61-5757) | Limited Availability | Other | |
| 250mg/5mL 100 mL (NDC 0781-60-4146) | Limited Availability | Other | |
| 250mg/5mL 150 mL (NDC 0781-60-4155) | Limited Availability | Other | |
| 250mg/5mL 80 mL (NDC 0781-60-4158) | Limited Availability | Other |
Teva Pharmaceuticals (Revised 05/23/2023)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| 200 mg/5mL (NDCs 0093-4160-73, 0093-4160-76, and 0093-4160-78) | (NDC 0093-4160-73) - Allocation of Limited Supply, Recovery expected May 2023; (NDC 0093-4160-76) - Allocating Available Supply; (NDC 0093-4160-78) - Allocating Available Supply ; | Demand increase for the drug | |
| 250 mg/5mL (NDCs 0093-4155-73, 0093-4155-80, and 0093-4155-79) | (NDC 0093-4155-73) - Allocating Available Supply; (NDC 0093-4155-80) - Allocating Available Supply; Recovery estimated May 2023; (NDC 0093-4155-79) - Allocating Available Supply; Recovery estimated May 2023 | Demand increase for the drug | |
| 400 mg/5mL (NDCs 0093-4161-73, 0093-4161-76, and 0093-4161-78) | (NDC 0093-4161-73) - Allocation of Limited Supply Recovery estimated July 2023; (NDC 0093-4161-76) - Allocation, of Limited Supply Recovery expected November 2024; (NDC 0093-4161-78) - Allocating Available Supply, Recovery estimated June 2023 | Demand increase for the drug |